Dilated cardiomyopathy
Conditions
Interventions
Control group:Conventional Western medicine treatment group
Treatment group:Shen'ge Powder Combined with Conventional Western Medicine
Sponsors
Shanghai Fifth Peoople's Hospital
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria of Western medicine and traditional Chinese medicine syndrome diagnosis of dilated cardiomyopathy; (2) Cardiac function grade (NYHA) grade II-IV; (3) Age 35-80 years; (4) During the test, other traditional Chinese medicines or intravenous preparations of traditional Chinese medicine were not used at the same time; (5) Those who agree to participate in clinical trial observation and can persist in completing treatment and observation index testing; (6) Signed and dated informed consent.
Exclusion criteria
Exclusion criteria: (1) History of acute myocardial infarction, coronary stent implantation, coronary artery bypass grafting; Patients with severe arrhythmias, pulmonary embolism, shock and other life-threatening diseases such as ventricular tachycardia, second-degree and type II atrioventricular block; (2) Patients with bronchial asthma, chronic bronchitis, cor pulmonale, and chronic obstructive pulmonary disease; (2) Patients with severe liver and kidney insufficiency, hyperthyroidism, hypothyroidism, anemia and electrolyte imbalance; (3) Pregnant or lactating women; (4) Patients with serious internal diseases, such as respiratory system, digestive system, blood system, immune system or diseases that may pose serious danger to patients; (5) Allergies or allergies to common drugs; (6) Those who have recently participated in other clinical research studies of traditional Chinese medicine or those who are currently taking other traditional Chinese medicines regularly and are unwilling to stop taking them; (7) Patients with mental illness or poor compliance with traditional Chinese medicine treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy and improvement of cardiac function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiography;NT-proBNP;Evaluation of the efficacy of TCM syndrome;TGF-ß1;Lee's heart failure score; | — |
Countries
China
Contacts
Public ContactZhou Chang
Shanghai Fifth Peoople's Hospital
Outcome results
None listed